Skip to main content
. 2020 Sep 24;12(1):1813962. doi: 10.1080/19420862.2020.1813962

Figure 3.

Figure 3.

Scheme of mPBPK/TE model for the CNTO 5048 interaction with TNF in serum and colon. (a) Basic second-generation minimal PBPK was used to characterize serum CNTO 5048 pharmacokinetics; (b) Colon compartments were incorporated into the basic mPBPK model to characterize colon CNTO 5048 distribution; (c) TMDD in the serum compartment was integrated into Model B to characterize the free TNF profile in serum; and (d) TMDD in the colon compartment was added to Model C to characterize the free TNF dynamics in colon.